Skip to main content
main-content

24-02-2022 | ASCO GU 2022 | Conference coverage | Video

Support for continuing enzalutamide after mCRPC progression

share
SHARE

Axel Merseburger discusses the results of the PRESIDE trial of enzalutamide rechallenge in metastatic castration-resistant prostate cancer in the context of the current treatment landscape, and outlines unanswered questions (4:35).

ESMO 2022 congress coverage

Access the latest news and expert insight from the 2022 European Society for Medical Oncology Congress

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.